Table 1.
Black and white patient cohort: patient and tumor characteristics
| White patients |
Black patients |
|||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | Neoadjuvant N (%) | Adjuvant N (%) | Total | Chi-Square (p-value) | Neoadjuvant N (%) | Adjuvant N (%) | Total | Chi-Square (p-value) |
| All | 40 (15.87%) | 212 (84.13%) | 252 | 92 (19.45%) | 381 (80.55%) | 473 | ||
| Age | 0.92 | 0.007 | ||||||
| <50 | 11 (27.50%) | 60 (28.30%) | 71 | 45 (48.91%) | 129 (33.86%) | 174 | ||
| >50 | 29 (72.50%) | 152 (71.70%) | 181 | 47 (51.09%) | 252 (66.14%) | 299 | ||
| Stage* | 0.68 | <0.0001 | ||||||
| II | 27 (67.50%) | 150 (70.75%) | 177 | 50 (54.35%) | 287 (75.33%) | 337 | ||
| III | 13 (32.50%) | 62 (29.25%) | 75 | 42 (45.65%) | 94 (24.67%) | 136 | ||
| ER status | 0.01 | 0.0003 | ||||||
| Negative | 15 (37.50%) | 41 (19.34%) | 56 | 53 (57.61%) | 140 (36.75%) | 193 | ||
| Positive | 25 (62.50%) | 171 (80.66%) | 196 | 39 (42.39%) | 241 (63.25%) | 280 | ||
| PR status1 | <0.0001 | 0.005 | ||||||
| Negative | 25 (62.50%) | 68 (32.08%) | 93 | 60 (66.67%) | 190 (50.26%) | 250 | ||
| Positive | 15 (37.50%) | 144 (67.92%) | 159 | 30 (33.33%) | 188 (49.74%) | 218 | ||
| HER2 status2 | <0.0001 | 0.09 | ||||||
| Equivocal | 4 (10.00%) | 0 (0.00%) | 4 | 1 (1.14%) | 0 (0.00%) | 1 | ||
| Negative | 28 (70.00%) | 170 (80.19%) | 198 | 71 (80.86%) | 281 (77.41%) | 352 | ||
| Positive | 8 (20.00%) | 42 (19.81%) | 50 | 16 (18.18%) | 82 (22.59%) | 98 | ||
| Triple-negative status3 | 0.02 | 0.0002 | ||||||
| No | 28 (70.00%) | 181 (85.38%) | 209 | 46 (57.27%) | 262 (72.58%) | 308 | ||
| Yes | 12 (30.00%) | 31 (14.62%) | 43 | 42 (47.73%) | 99 (27.42%) | 141 | ||
*
Clinical stage was used for neoadjuvant and pathological stage for adjuvant cohort.
1
PR status missing from 8 patients: Blacks/Neoadjuvant, N=90; Blacks/Adjuvant, N=378.
2
HER2 status missing from 25 patients: Blacks/Neoadjuvant, N=88; Blacks/Adjuvant, N=363.
3
Triple-negative status missing from 27 patients: Blacks/Neoadjuvant, N=88; Black/Adjuvant 361.
ER = estrogen receptor; PR = progesterone receptor; HER2 = Human Epidermal Growth Factor Receptor 2